Pharmaceuticals, Biotechnology and Life Sciences
Bristol-Myers Squibb said on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
There are few drugs available for the treatment of the disease, and those currently available have generally poor tolerability. As a result, CTCL patients and their physicians require safe and effective new treatment options, said Dr Richard Bethell, Medivir’s Chief Scientific Officer.
Array BioPharma said on Sunday it has exited the U.S. Food and Drug Administration’s (FDA) Division of Oncology Products 2 its new drug application (NDA) for binimetinib monotherapy for the treatment of NRAS-mutant melanoma, a rare, mutationally-driven subset of skin cancer.
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, has announced that its leveraged business unit has signed a programme in-licensing and option agreement with Servier, the independent French research-based pharmaceutical company .
Veidekke’s Danish subsidiary Hoffmann has been awarded a contract to build a new national research and treatment centre for particle therapy in Aarhus in Jutland.
Biofrontera, the biopharmaceutical company focusing on sun-induced skin cancer, has announced that preliminary long-term results of the Phase III trial for…
The European Commission has approved the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with…
You must be logged in to post a comment.